Post-hoc statistical adjustments and single-arm designs cannot substitute for randomized clinical evidence.
Faced with trial design deviations, regulatory agencies reject attempts to substantiate efficacy through post-unblinding modifications or uncontrolled single-arm studies.
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
The FDA's skepticism over Replimune's candidate stems from the inherent difficulties of proving efficacy using a single-arm study design without a randomized control.
The clinical efficacy data was deemed too fragile because the trial did not show a clear benefit under its original prespecified statistical parameters.
The FDA challenged Capricor's efficacy claims because they relied on post-hoc analytical adjustments rather than robust, pre-specified randomized clinical evidence.
The FDA and its advisory committee rejected the therapy's efficacy claims because they relied on late-stage changes to the statistical plan rather than the original prespecified design.
The regulatory standoff stems from the developer altering its statistical plan post-hoc to show success after the original parameters failed.
The advisory committee rejected the therapy because its efficacy claims relied on post-hoc statistical adjustments rather than prespecified randomized trial endpoints.
Regulators rejected the drug candidate because the trial failed to show effectiveness under the original prespecified plan before post-unblinding adjustments were made.